Status:

COMPLETED

Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)

Lead Sponsor:

AstraZeneca

Conditions:

Asthma

Eligibility:

All Genders

2-6 years

Phase:

PHASE3

Brief Summary

The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo....

Eligibility Criteria

Inclusion

  • Main
  • Written informed consent by the parents or legal guardians of the patient
  • Outpatients
  • Good health with the exception of asthma
  • Documented diagnosis of asthma for more than 6 months
  • Use of rescue medication only or pretreatment with a controller drug
  • Main

Exclusion

  • Concomitant severe diseases
  • Diseases contraindicated for the use of inhaled steroids
  • Other relevant lung diseases causing impairment in pulmonary function
  • Recurrent, episodic wheezing only
  • History of life-threatening asthma
  • History of any mechanical ventilation
  • Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
  • Premature birth (\< 32 weeks gestation)

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2007

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT00163449

Start Date

November 1 2005

End Date

May 1 2007

Last Update

December 8 2016

Active Locations (96)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 24 (96 locations)

1

Altana Pharma/Nycomed

Campinas - SP, Brazil, 13081970

2

Altana Pharma/Nycomed

Curitiba-PR, Brazil, 80060900

3

Altana Pharma/Nycomed

Paraná, Brazil, 80060900

4

Altana Pharma/Nycomed

Pinheiros Sao Paulo - SP, Brazil, 1246-000